Literature DB >> 3417288

Observer variation in histologic classification of malignant and borderline ovarian tumors.

H Stalsberg1, V Abeler, G P Blom, L Bostad, E Skarland, G Westgaard.   

Abstract

Eight hundred sixty-nine primary malignant or borderline ovarian tumors reported to the Norwegian Cancer Registry were reviewed. The histologic slides were randomly distributed to six observers and classified according to the World Health Organization classification of ovarian tumors. By rotation of slides, each tumor was successively reviewed by three observers. Each observer was given approximately 40 duplicates of slides he or she had typed before, mixed in with the slides for the third review. A contracted version of the classification with 27 entries was used in the analysis. Mean intraobserver reproducibility was 62% (kappa, 0.53), varying from 50% to 75% (kappa, 0.34 to 0.70) for the individual observers. The mean rate of agreement between two observers was 56% (kappa, 0.46), varying from 46% to 65% for the individual pairs of observers. The rate of full agreement among three observers was 41%. The most common disagreements were between different specific types of carcinoma, between undifferentiated and differentiated carcinoma, between borderline and malignant tumors, between unclassified and classified carcinoma, and between mixed and pure types of carcinoma. Very low reproducibility was obtained for mixed and unclassified carcinoma.

Entities:  

Mesh:

Year:  1988        PMID: 3417288     DOI: 10.1016/s0046-8177(88)80082-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.

Authors:  Catherine M Olsen; Christina M Nagle; David C Whiteman; Roberta Ness; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Harvey A Risch; Herbert Yu; Jennifer A Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T Goodman; Michael E Carney; Rayna K Matsuno; Galina Lurie; Kirsten Moysich; Susanne K Kjaer; Allan Jensen; Estrid Hogdall; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Cathrine Hoyo; Patricia Moorman; Rachel P Weber; Daniel W Cramer; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Lorna Rodriguez-Rodriguez; Melony King; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Penelope M Webb
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

Review 2.  Low-grade serous ovarian cancer: a unique disease.

Authors:  Kathleen M Schmeler; David M Gershenson
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

3.  Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.

Authors:  Diana Lim; Rajmohan Murali; Melissa P Murray; Emanuela Veras; Kay J Park; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2016-03       Impact factor: 6.394

4.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

Authors:  T Bjørge; A K Lie; E Hovig; R E Gislefoss; S Hansen; E Jellum; H Langseth; K Nustad; C G Tropé; A Dørum
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.